Stock Scorecard



Stock Summary for UroGen Pharma Ltd (URGN) - $26.93 as of 11/24/2025 10:00:17 PM EST

Total Score

7 out of 30

Safety Score

40 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for URGN

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for URGN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for URGN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for URGN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for URGN (40 out of 100)

Stock Price Rating (Max of 10) 7
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for URGN

UroGen ( URGN ) Q3 2025 Earnings Call Transcript 11/6/2025 4:03:00 PM
Urogen Pharma ( URGN ) Reports Q3 Loss, Misses Revenue Estimates 11/6/2025 2:15:00 PM
UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial 11/6/2025 12:58:00 PM
Adherex Technologies Inc. ( FENC ) May Report Negative Earnings: Know the Trend Ahead of Q3 Release 10/30/2025 2:00:00 PM
Biogen Inc. ( BIIB ) Q3 Earnings and Revenues Top Estimates 10/30/2025 11:15:00 AM
Urogen Pharma ( URGN ) Expected to Beat Earnings Estimates: Should You Buy? 10/29/2025 2:00:00 PM
MeiraGTx ( MGTX ) Moves 12.4% Higher: Will This Strength Last? 10/22/2025 12:18:00 PM
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer 10/2/2025 12:00:00 PM
UroGen Pharma to Present at Upcoming Investor Conferences 8/21/2025 12:00:00 PM
Urogen Pharma ( URGN ) Reports Q2 Loss, Lags Revenue Estimates 8/7/2025 1:15:00 PM

Financial Details for URGN

Company Overview

Ticker URGN
Company Name UroGen Pharma Ltd
Country USA
Description N/A
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 9/30/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 26.93
Price 4 Years Ago 9.51
Last Day Price Updated 11/24/2025 10:00:17 PM EST
Last Day Volume 1,478,409
Average Daily Volume 1,217,000
52-Week High 26.28
52-Week Low 3.42
Last Price to 52 Week Low 687.43%

Valuation Measures

Trailing PE N/A
Industry PE 43.52
Sector PE 86.12
5-Year Average PE -3.72
Free Cash Flow Ratio 14.03
Industry Free Cash Flow Ratio 13.25
Sector Free Cash Flow Ratio 27.29
Current Ratio Most Recent Quarter 3.99
Total Cash Per Share 1.92
Book Value Per Share Most Recent Quarter -2.47
Price to Book Ratio 19.27
Industry Price to Book Ratio 34.10
Sector Price to Book Ratio 33.20
Price to Sales Ratio Twelve Trailing Months 12.55
Industry Price to Sales Ratio Twelve Trailing Months 31.97
Sector Price to Sales Ratio Twelve Trailing Months 15.80
Analyst Buy Ratings 5
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 46,808,900
Market Capitalization 1,260,563,677
Institutional Ownership 100.71%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -24.09%
Reported EPS 12 Trailing Months -3.47
Reported EPS Past Year -2.66
Reported EPS Prior Year -3.23
Net Income Twelve Trailing Months -164,642,000
Net Income Past Year -126,874,000
Net Income Prior Year -102,244,000
Quarterly Revenue Growth YOY 9.00%
5-Year Revenue Growth 449.77%
Operating Margin Twelve Trailing Months -99.70%

Balance Sheet

Total Cash Most Recent Quarter 90,039,000
Total Cash Past Year 171,987,000
Total Cash Prior Year 95,002,000
Net Cash Position Most Recent Quarter -32,072,000
Net Cash Position Past Year 50,253,000
Long Term Debt Past Year 121,734,000
Long Term Debt Prior Year 98,551,000
Total Debt Most Recent Quarter 122,111,000
Equity to Debt Ratio Past Year -0.08
Equity to Debt Ratio Most Recent Quarter -17.22
Total Stockholder Equity Past Year -8,803,000
Total Stockholder Equity Prior Year -65,212,000
Total Stockholder Equity Most Recent Quarter -115,408,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -138,125,000
Free Cash Flow Per Share Twelve Trailing Months -2.95
Free Cash Flow Past Year -97,061,000
Free Cash Flow Prior Year -76,570,000

Options

Put/Call Ratio 1.90
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 1.51
MACD Signal 1.20
20-Day Bollinger Lower Band 14.13
20-Day Bollinger Middle Band 18.96
20-Day Bollinger Upper Band 23.78
Beta 1.26
RSI 62.52
50-Day SMA 13.56
150-Day SMA 13.49
200-Day SMA 12.12

System

Modified 11/22/2025 10:37:02 AM EST